Evaluation of Soluble Mesothelin-related Peptide as a Diagnostic Marker of Malignant Pleural Mesothelioma Effusions: Its Contribution to Cytology

REFERENCES

• Aziz T, Jilaihawi A, Prakash D. The management of malignant pleural mesothelioma; single centre experience in 10 years. Eur J Cardiothorac Surg 2002;22:298–305.
   PubMed Web of Science ®Google Scholar
• Borasio P, Berruti A, Billé A, Lausi P, Levra MG, Giardino R, Ardissone F. Malignant pleural mesothelioma: clinicopathologic and survival characteristics in a consecutive series of 394 patients. Eur J Cardiothorac Surg 2008;33:307–313.
   PubMed Web of Science ®Google Scholar
• Yates DH, Corrin B, Stidolph PN, Browne K. Malignant mesothelioma in south east England: clinicopathological experience of 272 cases. Thorax 1997;52:507–512.
   PubMed Web of Science ®Google Scholar
• Greillier L, Baas P, Welch JJ, Hasan B, Passioukov A. Biomarkers for malignant pleural mesothelioma: current status. Mol Diagn Ther 2008;12:375–390.
   PubMed Web of Science ®Google Scholar
• Light RW. The undiagnosed pleural effusion. Clin Chest Med. 2006;27:309–319.
   Google Scholar
• Neragi-Miandoab S. Malignant pleural effusion, current and evolving approaches for its diagnosis and management. Lung Cancer 2006;54:1–9.
   PubMed Web of Science ®Google Scholar
• Renshaw AA, Dean BR, Antman KH, Sugarbaker DJ, Cibas ES. The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma. Chest 1997;111:106–109.
   PubMed Web of Science ®Google Scholar
• Rakha EA, Patil S, Abdulla K, Abdulkader M, Chaudry Z, Soomro IN. The sensitivity of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma. Diagn Cytopathol 2010;38:874–879.
   PubMed Web of Science ®Google Scholar
• Grigoriu BD, Grigoriu C, Chahine B, Gey T, Scherpereel A. Clinical utility of diagnostic markers for malignant pleural mesothelioma. Monaldi Arch Chest Dis 2009;71:31–38.
   PubMedGoogle Scholar
• Ray M, Kindler HL. Malignant pleural mesothelioma: an update on biomarkers and treatment. Chest 2009;136:888–896.
   PubMed Web of Science ®Google Scholar
• Roncella S, Ferro P, Franceschini MC, Bacigalupo B, Dessanti P, Sivori M, Carletti AM, Fontana V, Canessa PA, Pistillo MP, Fedeli F. Diagnosis and origin determination of malignant pleural effusions through the use of the breast cancer marker human mammaglobin. Diagn Mol Pathol 2010;19:92–98.
   PubMed Web of Science ®Google Scholar
• Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA 1996;93:136–140.
   PubMed Web of Science ®Google Scholar
• Chang K, Pai LH, Pass H, Pogrebniak HW, Tsao MS, Pastan I, Willingham MC. Pass H. Monoclonal antibody K1 reacts with epithelial mesothelioma but not with lung adenocarcinoma. Am J Surg Pathol 1992;16:259–268.
   PubMed Web of Science ®Google Scholar
• Ordóñez NG. Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod Pathol 2003;16:192–197.
   PubMed Web of Science ®Google Scholar
• Beyer HL, Geschwindt RD, Glover CL, Tran L, Hellstrom I, Hellstrom KE, Miller MC, Verch T, Allard WJ, Pass HI, Sardesai NY. MESOMARK: a potential test for malignant pleural mesothelioma. Clin Chem 2007;53:666–672.
   PubMed Web of Science ®Google Scholar
• Creaney J, Francis RJ, Dick IM, Musk AW, Robinson BW, Byrne MJ, Nowak AK. Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical J stage and changes in tumor burden. Clin Cancer Res 2011;17:1181–1189.
   PubMed Web of Science ®Google Scholar
• Cristaudo A, Foddis R, Vivaldi A, Guglielmi G, Dipalma N, Filiberti R, Neri M, Ceppi M, Paganuzzi M, Ivaldi GP, Mencoboni M, Canessa PA, Ambrosino N, Chella A, Mutti L, Puntoni R. Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer. Clin Cancer Res 2007;13:5076–5081.
   PubMed Web of Science ®Google Scholar
• Luo L, Shi HZ, Liang QL, Jiang J, Qin SM, Deng JM. Diagnostic value of soluble mesothelin-related peptides for malignant mesothelioma: a meta-analysis. Respir Med 2010;104:149–156.
   PubMed Web of Science ®Google Scholar
• Robinson BW, Creaney J, Lake R, Nowak A, Musk AW, de Klerk N, Winzell P, Hellstrom KE, Hellstrom I. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003;36:1612–1616.
   Google Scholar
• Schneider J, Hoffmann H, Dienemann H, Herth FJ, Meister M, Muley T., Dienemann H. Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer. J Thorac Oncol. 2008;3:1317–1324.
   PubMed Web of Science ®Google Scholar
• Wheatley-Price P, Yang B, Patsios D, Patel D, Ma C, Xu W, Leighl N, Feld R, Cho BC, O'Sullivan B, Roberts H, Tsao MS, Tammemagi M, Anraku M, Chen Z, de Perrot M, Liu G. Soluble mesothelin-related peptide and osteopontin as markers of response in malignant mesothelioma. J Clin Oncol 2010;28:3316–3322.
   PubMed Web of Science ®Google Scholar
• Alemán C, Manuel Porcel J, Ma Segura R, Alegre J, Esquerda A, Ruiz E, Bielsa S, de Sevilla TF. Pleural fluid mesothelin for the differential diagnosis of exudative pleural effusions. Med Clin (Barc) 2009;133:449–453.
   PubMed Web of Science ®Google Scholar
• Creaney J, Yeoman D, Naumoff LK, Hof M, Segal A, Musk AW, De Klerk N, Horick N, Skates SJ, Robinson BW. Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma. Thorax 2007;62:569–576.
   PubMed Web of Science ®Google Scholar
• Davies HE, Sadler RS, Bielsa S, Maskell NA, Rahman NM, Davies RJ, Ferry BL, Lee YC. Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions. Am J Respir Crit Care Med 2009;180:437–444.
   PubMed Web of Science ®Google Scholar
• Pass HI, Wali A, Tang N, Ivanova A, Ivanov S, Harbut M, Carbone M, Allard J. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. Ann Thorac Surg 2008;85:265–272.
   PubMed Web of Science ®Google Scholar
• Scherpereel A, Grigoriu B, Conti M, Gey T, Grégoire M, Copin MC, Devos P, Chahine B, Porte H, Lassalle P. Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 2006;173:1155–1160.
   PubMed Web of Science ®Google Scholar
• Yamada S, Tabata C, Tabata R, Fukuoka K, Nakano T. Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma. Clin Chem Lab Med 2011;49:1721–1726.
   PubMed Web of Science ®Google Scholar
• Gennaro V, Ugolini D, Viarengo P, Benfatto L, Bianchelli M, Lazzarotto A, Montanaro F, Puntoni R. Incidence of pleural mesothelioma in Liguria region, Italy (1996–2002). Eur J Cancer 2005;41:2709–2714.
   PubMed Web of Science ®Google Scholar
• Marinaccio A, Binazzi A, Di Marzio D, Scarselli A, Verardo M, Mirabelli D, Gennaro V, Mensi C, Merler E, De Zotti R, Romanelli A, Chellini E, Silvestri S, Pascucci C, Forastiere F, Menegozzo M, Musti M, Cauzillo G, Nicita C, Melis M, Iavicoli S; ReNaM Working Group. Il registro nazionale dei mesoteliomi: risultati, interpretazione, commento ai dati. Il registro Nazionale dei Mesoteliomi. Istituto Superiore per la prevenzione e la sicurezza del lavoro 2001; Terzo rapporto; 27–34.
   Google Scholar
• Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuyt PM. The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol 2003;56:1129–1135.
   PubMed Web of Science ®Google Scholar
• Pepe MS. The Statistical Evaluation of Medical Tests for Classification and Prediction. Oxford, UK: Oxford University Press, 2003.
   Google Scholar